873697-59-7

Basic information

• Product Name: 3-(4-Boc-piperazin-1-yl-methyl)-5-fluoroaniline
• Synonyms: 3-(4-Boc-piperazin-1-yl-methyl)-5-fluoroaniline
• CAS NO: 873697-59-7
• Molecular Formula: C₁₆H₂₄FN₃O₂
• Molecular Weight: 309.38
• Mol File: 873697-59-7.mol

Chemical Properties

• Boiling Point: 416.732°C at 760 mmHg
• Flash Point: 205.832°C
• Appearance: /
• Density: 1.187g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.556
• CAS DataBase Reference: 3-(4-Boc-piperazin-1-yl-methyl)-5-fluoroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Boc-piperazin-1-yl-methyl)-5-fluoroaniline(873697-59-7)
• EPA Substance Registry System: 3-(4-Boc-piperazin-1-yl-methyl)-5-fluoroaniline(873697-59-7)

Safety Data

• Hazardous Substances Data: 873697-59-7(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
3-(4-Boc-piperazin-1-yl-methyl)-5-fluoroaniline is used as a building block for the synthesis of various biologically active molecules. Its structural features make it a versatile intermediate for the development of new drugs and agrochemicals.
Used in Pharmaceutical Research:
3-(4-Boc-piperazin-1-yl-methyl)-5-fluoroaniline is used as a valuable tool for studies involving fluorine chemistry, which can contribute to the development of new pharmaceutical compounds with improved properties.
Used in Fluorine Chemistry Studies:
3-(4-Boc-piperazin-1-yl-methyl)-5-fluoroaniline is used as a valuable tool for studies involving fluorine chemistry, which can lead to the discovery of new synthetic methods and applications in various fields.

InChI:InChI=1/C16H24FN3O2/c1-16(2,3)22-15(21)20-6-4-19(5-7-20)11-12-8-13(17)10-14(18)9-12/h8-10H,4-7,11,18H2,1-3H3

Upstream product

• 873697-58-6 C₁₆H₂₂FN₃O₄ 

Downstream Products

• 873697-60-0 C₂₃H₃₀FN₅O₃ 

Relevant articles and documents

Compounds, Compositions and Methods

Certain substituted urea derivatives modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Certain substituted urea derivatives modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, cachexia, neuromuscular diseases (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, familial or acquired myopathies or muscular dystrophies), post-surgical and post-traumatic muscle weakness, and other conditions.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

COMPOUNDS, COMPOSITIONS AND METHODS

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Compounds, compositions and methods

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.